[1] Jager PL, de Korte MA, Lub-de Hooge MN, et al. Molecular imaging:what can be used today[J/OL]. Cancer Imaging, 2005, 5(spec No A):S27-32[2014-09-01]. http://www. ncbi. nlm. nih. gov/pmc/ articles/PMC1665304/.
[2] Yap CS, Czernin J, Fishbein MC, et al. Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography[J]. Chest, 2006, 129(2):393-401.
[3] Stahl A, Ott K, Weber WA, et al. FDG PET imaging of locally advanced gastric carcinomas:correlation with endoscopic and histopathological findings[J]. Eur J Nucl Med Mol Imaging, 2003, 30(2):288-295.
[4] Kim SK, Allen-Auerbach M, Goldin J, et al. Accuracy of PET/CT in characterization of solitary pulmonary lesions[J]. J Nucl Med, 2007, 48(2):214-220.
[5] Tan Y, Liang J, Liu D, et al. 18F-FLT PET/CT imaging in a Wister rabbit inflammation model[J]. Exp Ther Med, 2014, 8(1):69-72.
[6]

McKinley ET, Ayers GD, Smith RA, et al. Limits of[18F]-FLT PET as a biomarker of proliferation in oncology[J/OL]. PLoS One, 2013, 8(3): e58938[2014-09-01]. http://www. ncbi. nlm. nih. gov/23554961.

[7] Lin PL, Rodgers M, Smith L, et al. Quantitative comparison of active and latent tuberculosis in the cynomolgus macaque model[J]. Infect Immun, 2009, 77(10):4631-4642.
[8] Zhao S, Kuge Y, Kohanawa M, et al. Usefulness of 11C-methionine for differentiating tumors from granulomas in experimental rat models:a comparison with 18F-FDG and 18F-FLT[J]. J Nucl Med, 2008, 49(1):135-141.